TL;DR
Subclinical liver fibrosis is surprisingly prevalent in patients with aneurysmal subarachnoid hemorrhage (aSAH) and is a strong independent predictor of 90-day mortality and rebleeding. Integrating simple, blood-based liver fibrosis scores into standard clinical models significantly improves our ability to identify high-risk patients.
What Problem Does This Paper Address?
Aneurysmal subarachnoid hemorrhage (aSAH)—a type of stroke caused by a ruptured brain aneurysm—is a medical emergency with a staggering 35% mortality rate. While clinicians use established scales (like the Hunt & Hess or Fisher grades) to predict outcomes, these focus almost exclusively on neurological status and imaging.
The "liver-brain axis" is often overlooked in acute neurosurgery unless a patient has overt cirrhosis. However, the liver is central to systemic inflammation and blood coagulation—two factors critical to surviving a brain bleed. This paper investigates whether subclinical liver fibrosis (scarring of the liver that hasn't yet reached the stage of cirrhosis) is common in aSAH patients and whether it can help predict who will survive and who is at risk of dangerous "rebleeding" events.
Methods
The researchers conducted a retrospective cohort study of 3,722 patients admitted to West China Hospital between 2009 and 2019. To assess liver health without the need for invasive biopsies, they used three validated, non-invasive scoring systems calculated from standard admission blood work:
- APRI: Aspartate aminotransferase (AST) to Platelet Ratio Index.
- FIB-4 index: Uses age, AST, Alanine aminotransferase (ALT), and platelet count.
- Forns index: Uses age, platelets, GGT (gamma-glutamyl transferase), and cholesterol.
The team then compared these scores against the SAHIT (Subarachnoid Hemorrhage International Trialists) model, the gold standard for aSAH prognosis, to see if adding liver data improved the model's accuracy.
Datasets
The study utilized a large, single-center dataset from the electronic medical records of West China Hospital, Sichuan University.
- Sample Size: 3,722 eligible patients.
- Validation: Mortality data was cross-referenced with the official Household Registration Administration System of Sichuan province to ensure accuracy up to 90 days (and up to 3 years for secondary analysis).
Key Insights and Ideas
- High Prevalence of "Hidden" Liver Disease: Depending on the index used, between 11.4% and 21.7% of aSAH patients had significant liver fibrosis. This suggests that a large portion of the patient population has compromised liver function that goes unnoticed during standard neurological intake.
- The Rebleeding Connection: High liver fibrosis scores were significantly associated with an increased risk of rebleeding. This is likely because the liver produces the clotting factors necessary to stabilize a ruptured aneurysm; a scarred liver may fail to provide this "biological glue."
- Beyond the Brain: The study reinforces the idea that aSAH is a systemic disease. A patient’s baseline metabolic and hepatic health may be just as important as the size of the aneurysm itself.
- Simple Integration: Because these indices (FIB-4, APRI) rely on routine lab tests, they offer a "free" way to improve risk stratification without additional expensive imaging or invasive procedures.
Key Results
- Mortality Risk: After adjusting for age, sex, and stroke severity, patients with high liver fibrosis scores had a much higher risk of 90-day mortality. The Odds Ratios (OR) were 1.35 for FIB-4, 1.39 for APRI, and 1.53 for the Forns index.
- Improved Prediction: Adding FIB-4 or APRI to the standard SAHIT model significantly increased the Area Under the Curve (AUC) and the Net Reclassification Improvement (NRI). Specifically, the addition of APRI yielded a 22.6% improvement in correctly reclassifying patient risk.
- Correlation: All three liver indices were strongly correlated with each other, suggesting they are picking up on the same underlying physiological stress.
Limitations and Future Work
- Retrospective Nature: As an observational study, it can show association but not direct causation. It remains unclear if treating the liver dysfunction could actually improve aSAH outcomes.
- Single-Center Study: The data comes from a single province in China. Liver disease prevalence and aSAH outcomes can vary significantly across different ethnic groups and healthcare systems.
- Single Measurement: Liver scores were only calculated at admission. The authors note that they did not track how liver function changed over the course of the hospital stay, which could provide even more granular prognostic data.
- Future Directions: The authors suggest that future research should explore the specific biological mechanisms—such as systemic inflammation or specific coagulation pathways—that link liver scarring to poor neurological recovery.
Summary updated